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come to allopathic medicine.. Furthermore, living in the
same community as their patients, traditional healers know
about the disease pattern of that community. If well trained,
they can identify diseases that can be prevented or
modified, and they are sometimes able to cure some
diseases.
Traditional healers are respected in African villages. They
are community leaders and members who can encourage
community participation. If consulted they can encourage
their fellow community members to help prevent and cure
many ailments. Health workers should therefore encourage
rapport between themselves and traditional healers.
Unfortunately, however, many modern health workers scorn
traditional healing.
Conclusion
In a black African setting, traditional healing is the first and
nearest contact with a health care system. It is therefore by
definition the African's primary health care. Further
incorporating traditional healers into modern health care
systems would help identify diseases before they reach an
advanced stage and the patient becomes disabled or dies
because valuable time has been wasted. Traditional healers
should also be encouraged to refer patients they are
incapable of curing or treating.
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South African Childhood Asthma Working Group
Objective. To make recommendations regarding the
treatment of chronic asthma to achieve effective control;
to emphasise that asthma is a clinical diagnosis; to stress
the central role of inflammation in asthma; to recommend
alternative agents for practice where certain drugs are not
available; and to address new agents that have been
introduced for the treatment of asthma.. ."
Options. A new severity grading of mild, modera~e and
severe asthma is proposed to aid in the selection ot
medication. This severity assessment uses four features;
attack frequency, nocturnal symptom frequency, hospital
admissions and peak flow. Since asthma can vary with
time, regular reassessment with a view to reassignment of
individual grading is necessary.
Outcomes. Goals of effective control strive to ensure
that the asthmatic leads a normal life free from symptoms
with regular school attendance, restful sleep, nonnal
growth and development, minimal acute attacks and
avoidance of hospital admissions.
Evidence. Previous local and international consensus
statements.
Benerlts, harms, costs. Early diagnosis, accurate
grading and effective control reduce morbidity and
mortality and will be cost-saving. Phannaco-economic
evaluations of the cost of asthma show that medications
per se represent a small percentage of the overall cost of
asthma.
Recommendations. Inhaled therapy is preferred, even in
young children, as aerosol devices for all ages are
available. Mild asthma is treated with intermittent short-
acting f3-agonists, moderate asthma with regular
cromoglycate and severe asthma with regular inhaled
steroids. Environmental control, specialist referral and
hazardous and unnecessary therapy are also addressed.
Sponsors. Roche Phannaceuticals.
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The South African Childhood Asthma Working Group
(SACAWG) convened on 5 February 1994 to review its
previous gUidelines for the management of chronic
childhood and adolescent asthma.' The previous gUidelines
needed changing because:
1. The scoring system presented proved impractical.
2. The central role of inflammation in asthma needed to
be stressed.
3. Umited availability of certain drugs in rural areas
required alternative agents to be suggested.
4. New inhaled long-acting ~2-agonists and inhaled
steroids have been introduced.
The consensus group found that it is extremely difficult to
assign an assessment of severity or a scoring system to
chronic asthma, because children with asthma present and
behave in very variable ways. In order to balance the
overtreatment and undertreatment of asthma we draw
attention to the two broad categories of chronic asthma
presentation: namely intermittent and/or mild symptoms,
and continuous/recurrent and/or moderate to severe
symptoms. In an attempt to achieve the goals of
management this first categorisation step aims to avoid the
situation of the treatment being worse than the disease. The
figure (p. 864) recommends intermittent ~2-agonists for the
former group and continuous anti-inflammatory therapy for
the latter. As has been shown, there are two groups of anti-
inflammatory agents, cromoglycate and inhaled steroids. In
cases where didactic categorisation is difficult, individual
practice habits will determine the initial anti-inflammatory of
choice. However, whichever drug is chosen for maintenance
therapy, the goals of therapy must be achieved (the patient
must be well controlled). This applies to step-up as well as
step-down therapy.
The dominant pathophysiological process underlying
asthma in children is airway inflammation. Asthma is the
commonest chronic disease in children and treatment may
be expensive. Resources in our country are limited and
alternative cheaper drugs will be recommended in this
statement. However, health practitioners should strive to
achieve the best possible therapy for each of their patients
through motivation and education of parents, manufacturers
and health administrators in order to ensure that appropriate
drugs are accessible to all patients.
Paediatric v. adult asthma
The differences between paediatric and adult asthma need
to be fully appreciated. In childhood and adolescence,
asthma is often triggered by environmental factors and
allergens. The diagnosis, assessment of severity and
monitoring of the effects of therapy are more difficult in
young children because it may not be possible to obtain
reliable objective measurement of airway obstruction. Acute
episodes of severe asthma often develop more rapidly in
young children.
Diagnosis
Asthma is a clinical diagnosis. Asthma must be diagnosed in
a child with phronic persistent or recurrent cough and/or
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wheeze that responds to a bronchodilator. Features
supporting the diagnosis are a family and personal history
of atopy, night cough, exercise-induced cough and/or
wheeze and a seasonal variation in symptoms. Furthermore,
additional support for the diagnosis in older children
(> 5 years) is objective evidence of reversible airways
obstruction. This can be obtained by measuring the peak
expiratory flow rate (PEFR) or forced expiratory volume in 1
second (FEV,) before and after ~2-agonist administration. An
improvement of more than 10% after 10 minutes indicates
reversible airways obstruction.
Assessment of severity and
control
The assessment presented has been kept as simple as
possible but does not constitute a compromise, as it
conforms to international assessment criteria. The following
points should be noted:
1. The assessment of severity is outlined in tabular form
in the figure on p. 864. A severity grading is important to
place the child into a partiCUlar treatment category.
2. The assessment of severity refers to a child with
regular or intermittent symptoms. The assessment and
management of the acute attack are dealt with in a previous
guideline!
3. Asthma presents as a spectrum of severity rather than
in discrete severity groups. Practitioners should attempt to
grade each patient accurately but must regard this only as a
starting point.
4. If unsure of grading, place the child on the most likely
therapy, provide a diary card (for symptoms and/or PEFR)
and reassess after 4 weeks.
5. One or more features may be present to assign a grade
of 'severity; a patient must be assigned to the most severe
grade in which any feature occurs.
6. Asthma can vary with time. Regular reassessment (at
least every 3 months) with a view to reassignment of
individual patients is necessary.
7. PEFR should not be used to classify patients during
acute attacks.
8. In practice about 70% of childhood asthmatics will fall
into the 'mild', 25% into the 'moderate' and 5% into the
'severe' categories.
Parents and patients should be taught that failure to
respond to two doses of inhaled bronchodilator given 30
minutes apart constitutes a severe attack of asthma. This




The goal is effective control of asthma, which strives to
ensure that the asthmatic is able to lead a normal and
physically active life. For a 'normal life' the aim is to:
1. Be completely free from any symptoms, i.e. cough,
wheeze and breathlessness.
SAMJ Volume 84 No. 12 December 1994 _
2. Attend school regularly and participate fully in all
school activities, including sports.
3. Have restful sleep free from night-time cough and/or
wheeze.
4. Grow and develop normally.
5. Minimise the number of attacks of acute asthma.
6. Avoid hospital admissions.
Principles
A comprehensive therapeutic approach is required to meet
the above objectives. This includes the following:
1. Early diagnosis and objective assessment of severity.
2. Control of the 'environment to exclude cigarette smoke
and reduce exposure to triggers such as viral infection and
allergens.
3. Optimal use of medications to limit side-effects and
cost.
4. Ensuring that the patient receives the correct therapy
by the most appropriate means (see 'Drug delivery
systems').
5. Follow-up and regular re-evaluation.
6. Education of the patient and family, which must
include: (I) stressing the diagnosis and explaining the nature
of the condition; (if) issuing a written plan of management;
(iif) informing all care-givers, including teachers; and
(iv) reassuring parents and patients of safety of continuous
regular therapy.
Environmental control
Certain aspects, where practical, need to be emphasised:
1. Cigarette smoking is harmful to asthmatics. Smoking
should not be allowed in the home of any asthmatic and
active steps should be taken to inform household members
of the problem, encouraging any smokers to quit. The need
to help their child can be a powerful incentive to parents to
quit smoking.
2. In the individual patient where house-dust mites have
been shown to be a problem, appropriate control measures
should be considered. These include plastic mattress
covers, removal of bedroom carpets, and washing blankets
in hot water (> 7D°C). Although acaricides such as benzyl
benzoate (Acarosan) are able to reduce house-dust mite
levels in carpets, they are ineffective when applied to
mattresses.
3. Pets should not sleep in children's bedrooms. In
addition, cats should be discouraged as pets in families with
allergic children.
4. Certain preservatives can be potent triggers (e.g.
benzoates and sulphites) and should be avoided.
Drug delivery systems
The inhaled method is the route of choice, as lower doses
can be used than with oral medication. Inhalation spacer
devices (Aerochamber, Fisonaire, Volumatic) enable parents
to administer aerosol therapy to children of all ages. If these
spacer devices are not available, spacers can be made from
a variety of cheap alternatives, e.g. polystyrene cups, plastic
bottles. If patients are on long-term inhaled therapy they
should preferably use a spacer device rather than a home-
made device. The ages at which different inhalers are
appropriate are: (I) spacer devices (with MOl) - birth to 5
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years; (if) powder devices - over 5 years; (UI) metered dose
inhalers (MOl) - over 8 years. These recommended age
ranges should serve only as a guide, as overlap often
occurs. Certain devices to improve efficacy of inhaler
therapy delivery outside these age ranges are now available,
e.g. Autohaler, Turbuhaler.
Lung function testing
PEFR can be measured by cheap hand-held devices
(Assess, Mini-Wright, Pocket peak flow, Vitalograph). They
give objective evidence of the degree of airway obstruction
and improvement on therapy. All children (> 5 years) should
have their peak flow measured during the initial evaluation
and at follow-up. Moderate and severe asthmatics should
receive peak flow meters to assess their condition at home.
Forced spirometry should be done periodically at follow-up
to confirm home peak flow measurements and assess small-
airway disease.
Principles of medication
When selecting medication for an asthmatic patient, the
following principles apply:
1. Asthma is an inflammatory disease of the airways.
2. RegUlar anti-inflammatory medication is indicated for
the moderate and severe categories.
3. Where ~2-agonists are used regularly (more than 3
times a week), daily anti-inflammatory therapy should be
prescribed.
4. Inhaled therapy is preferable.




Short acting ~2-agonists (rather than theophylline) should
be used as first-line bronchodilators in children because of
their wide margin of safety and freedom from serious side-
effects. Bronchodilators should be used intermittently for the
relief of symptoms rather than as regular maintenance
therapy. It is cheaper to use an inhaled ~2-agonist with a
spacer than most theophylline preparations.
2. Long-acting ~2-agonists
Formoterol (Foradil) and salmeterol (Serevent) can be used
in resistant nocturnal and exercise-induced asthma. When
required, these agents should be considered as an addition
to anti-inflammatory therapy in children with severe asthma.
3. Theophyllines
Where ~2-agonists or anti-inflammatory agents (inhaled
cromoglycate and steroids) are not available, theophylline
tablets and aqueous solution can be used for maintenance
therapy.3 Differing absorption profiles complicate treatment
using the long-acting preparations. Controversy as to the
correct therapeutic serum levels to advise further
complicates theophylline therapy. Practitioners are therefore
encouraged to motivate for the availability of anti-
inflammatory agents in their institution.
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4. Ipratropium bromide (Atrovent)
Ipratropium bromide may be a useful adjunct to regular
~2-agonist therapy in small children « 1 year) in whom
cough and/or wheeze are major symptoms.
Anti-infJammatories
1. Sodium cromoglycate (Lomudal)
Sodium cromoglycate (Lomudal) is indicated for the
prevention of moderate asthma. It must be taken regularly to
be effective to reduce bronchial hyper-reactivity.· It is also
useful in the prevention of exercise-induced asthma when
taken 30 minutes beforehand. Sodium cromoglycate is
remarkably safe in children.
2. Ketotifen (Zaditen)
Ketotifen (Zaditen) may be a useful adjunct to
bronchodilator therapy in young « 3 years old) highly
allergic children who have atopic eczema or hay fever in
addition to their asthma.
3. Inhaled steroids
Inhaled steroids should be used for prophylaxis in children
with severe asthma. Steroid therapy should be tailored to
the response documented by symptoms and, where
possible, respiratory function testing. The lowest possible
effective dose should be used. For inhaled beclomethasone
(Becotide, elenil, Ventzone, Viarox), budesonide (Inflammide,
Pulmicort) and fiuticasone (Flixotide), doses under 400
~g/day are associated with minimal side-effects. Where
higher doses are required, use of fluticasone (Flixotide),
which to date has demonstrated reduced systemic effects,
should be considered. The efficacy and safety of inhaled
steroids are increased by the use of spacer devices. Where
cromoglycate is not available, low-dose inhaled steroids
may be considered.
4. Oral steroids
Short courses (,,;;; 14 days) of oral steroids (prednisone
1 - 2 mg/kg/d) are generally necessary in the treatment of
exacerbations of asthma.' Maintenance treatment with daily
or alternate-day oral steroids is indicated only in those rare
patients not controlled by high-dose inhaled steroids. In
children on oral steroids extra care should be taken during
episodes of increased stress, e.g. surgery.
Other drugs - antihistamines
Antihistamines may be used for the treatment of hay fever in
asthmatics with hay fever.
Tapering and terminating
therapy
Children on anti-asthma therapy should be reviewed at least
every 3 months, and if well controlled should be considered
for reduction in treatment. Note that this should not be
attempted during the patient's worst season.
Referral to a specialist
Referral of patients to a specialist is recommended if the
goals of management are not achieved, or for the following
reasons:
1. Diagnosis in doubt.
2. Unstable asthma.
3. Asthma interferes with normal life despite treatment.
4. Parents or general practitioners need further support.
5. When oral steroids are required regularly.
6. After a life-threatening episode.
Unnecessary therapy
The following are without benefit in the treatment of
childhood asthma: antibiotics, cough syrups, mucolytics,
ionisers and breathing exercises. Physiotherapy is iQdicated
in children only where lobar collapse is documented.
Frequent visits to the physiotherapist must indicate to the
practitioner that the patient's maintenance anti-inflammatory
treatment needs revision. .
Hazardous therapy
Rectal aminophylline and immunotherapy are dangerous and
contraindicated in childhood asthma.
The SACAWG is an official working group of the Allergy
Society of South Africa. This meeting of the SACAWG was
sponsored by Roche Products.
These guidelines are endorsed by the Medical Association of
South Africa.
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